Ioannis C. Thomas

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: August 16, 2026

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part III: Transcranial Application, Immune Profile, Blood-Brain Barrier, Neuroprotection, Neuromodulation and Neurostimulation.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part III: Transcranial Application, Immune Profile, Blood-Brain Barrier, Neuroprotection, Neuromodulation and Neurostimulation.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: April 04, 2026

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part I: Animal Experiments, Clinical Application and Immunological Abscopal Effect.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part I: Animal Experiments, Clinical Application and Immunological Abscopal Effect.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: November 03, 2025

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Journal: Nature medicine

Published: September 12, 2025

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Journal: Journal for immunotherapy of cancer

Published: November 24, 2024

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Journal: American journal of clinical dermatology

Published: March 25, 2023

EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.

EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.

Journal: Journal of the American Academy of Dermatology

Published: February 28, 2023

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.

Journal: Lancet (London, England)

Published: November 15, 2022

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.

Journal: Cancers

Published: October 30, 2021

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.

Journal: Neuro-oncology advances

Published: December 11, 2020

Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.

Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.

Journal: Cancers

Published: March 09, 2020

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: October 10, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026